Daewon Pharmaceutical's DW4421 Shows Noninferiority to Esomeprazole in Phase 3 Reflux Trial

• Daewon Pharmaceutical reported positive Phase 3 results for DW4421 in erosive reflux disease on Oct. 29, 2026.
• Both 20 mg and 40 mg doses demonstrated noninferiority to esomeprazole 40 mg in complete healing of mucosal breaks.
• Adverse drug reaction rates were 4.59% for DW4421 40 mg, 3.74% for 20 mg and 3.7% for the comparator.
• The 328-patient trial recorded no serious adverse events; adverse drug reaction rates did not differ significantly between groups.
• Detailed efficacy and safety analyses will precede submission of the final report and a marketing application to South Korea's drug regulator.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daewon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029800655), on October 29, 2026, and is solely responsible for the information contained therein.